What is Bio-Techne Selling, General, & Admin. Expense?
Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Bio-Techne's selling, general, & admin. expense for the
three
months ended in Dec. 2023 was $116 Mil.
Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Dec. 2023 was $381 Mil.
Bio-Techne Selling, General, & Admin. Expense Historical Data
The historical data trend for Bio-Techne's Selling, General, & Admin. Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Bio-Techne Selling, General, & Admin. Expense Chart
Competitive Comparison of Bio-Techne's Selling, General, & Admin. Expense
For the Biotechnology subindustry, Bio-Techne's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Techne's Selling, General, & Admin. Expense Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Techne's Selling, General, & Admin. Expense distribution charts can be found below:
* The bar in red indicates where Bio-Techne's Selling, General, & Admin. Expense falls into.
Bio-Techne Selling, General, & Admin. Expense Calculation
Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.
Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $381 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Techne (NAS:TECH) Selling, General, & Admin. Expense Explanation
An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.
Warren Buffett likes companies with consistent SGA as the percentage of gross profit.
Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.
If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.
Bio-Techne Selling, General, & Admin. Expense Related Terms
Thank you for viewing the detailed overview of Bio-Techne's Selling, General, & Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TECH has been successfully added to your 